Accufix Surgical

Executive Summary

Accufix Surgical is a US-based medical device company specializing in orthopedic implants for joint preservation. Its flagship product, the Accu-Joint® Hemi implant system, is FDA-approved for treating metatarsophalangeal (MTP) joint disorders such as hallux rigidus and limitus. The company's technology focuses on restoring natural motion and avoiding traditional joint fusion, aiming to improve patient quality of life. Founded in 2015 and headquartered in San Diego, Accufix is privately held and operates at the 'Approved' stage, indicating commercial availability of its lead product. The company's differentiation lies in its joint preservation approach, which addresses a significant unmet need in foot and ankle surgery. As a commercial-stage entity, Accufix is positioned to capture market share in the orthopedic implant space, particularly among patients and surgeons seeking motion-sparing alternatives. Key growth drivers include expanding surgeon adoption, building clinical evidence, and potentially developing next-generation implants or expanding into adjacent indications. While financial details remain undisclosed, the company's FDA approval and focus on a validated clinical need provide a solid foundation for future growth.

Upcoming Catalysts (preview)

• Q4 2026Commercial adoption milestones for Accu-Joint Hemi implant system70% success
• Q2 2027Publication of clinical outcomes data supporting joint preservation benefits60% success
• TBDPotential strategic distribution or licensing partnership for market expansion50% success